Tagged with manufacturing

Indonesia Herny Prasetya, President of the International Society of Pharmaceutical Engineering (ISPE) in Indonesia highlights the importance of the implementation of global guidelines in Indonesia and wishes to focus on human capital, compliance and local API manufacturing for ISPE’s members. Could you please introduce to our international audience what are the…

Ukraine Tatyana Pechaeva, Managing Director of the Lekhim Group, one of Ukraine’s top ten domestic pharmaceutical companies, shares the main principles of her strategy which have enabled Lekhim to display high growth rates over recent years despite the country’s unstable economy. The Lekhim group of companies was one of the pioneers…

Taiwan Weichyun Wong, president of SCI Pharmtech, discusses the API manufacturer’s transition from a Swiss-owned affiliate to a Taiwanese company. He also talks technology and regulatory challenges, as well as what differentiates SCI Pharmtech from its competitors. SCI Pharmtech, Inc. has a long-standing presence in Taiwan. Could you tell us a…

Taiwan C.Y. Cheng, chairman and president of Formosa Laboratories, shares exciting news about the establishment of a new drug development company, Formosa Pharmaceuticals. He explains how the know-how gained from running a successful international API production business will help Formosa avoid the typical mistakes that young R&D companies face. Mr. Cheng,…

Taiwan Peter Tsai, founder, CEO, and chairman of Orient EuroPharma (OEP), one of the leading groups of healthcare companies in Taiwan, provides insights into his strategic vision to double the group’s revenues within the next five years and nurture the long-term growth of the company he founded in 1982, while OEP’s…

Taiwan Peter Tsai, founder, CEO, and chairman of Orient EuroPharma (OEP), one of the leading groups of healthcare companies in Taiwan, provides insights into his strategic vision to double the group’s revenues within the next five years and nurture the long-term growth of the company he founded in 1982, while OEP’s…

Switzerland Markus Arigoni, CEO of Ticino-based micronization specialists Micro-Macinazione, describes the scope of the company’s operations, the enlargement of the firm’s R&D capacities, and emerging trends in the micronization niche. Micro-Macinazione SA was founded back in 1970 and has subsequently developed into one of Europe’s most renowned providers of micronization of…

Mexico Ricardo Spínola, CEO at Farmapiel, explains his clear vision for the company and showcases the added value of Farmapiel’s product offering for both patients and healthcare professionals. Mr. Spínola you have more than 16 years of experience in top management positions for leading pharmaceutical companies and private hospitals. Nevertheless, in…

Switzerland Gabriel Haering, CEO of API manufacturer Cerbios, highlights the importance of “Swiss-ness” to the company’s brand, their attentiveness to diversification and scaling the value chain, and the future prospects for Swiss CMOs. Cerbios is renowned for its expertise in the process development and contract manufacturing of Active Pharmaceutical Ingredients (APIs) and…

Mexico Eduardo Arce Parellada, General Manager at Sanofi Pasteur Mexico until March 2017, explains the positive impact that the vaccine against Dengue could generate for the national health system and showcases the positioning of Sanofi Pasteur as the partner of choice for the government in vaccinology, based on its local R&D…

Switzerland The managing director of CordenPharma Switzerland elaborates on the role the Swiss facility plays within CordenPharma. He furthermore highlights how the company is tailoring their service offering to cater to the needs of multi-national companies, mid-sized companies as well as start-ups. You worked in various positions in Lonza for 27…

Ipsen These are exciting times for Ipsen in Ireland, with plans to expand the company’s already significant API manufacturing footprint to deal with increasing global demand for its products. “Sales from [Somatuline® (lanreotide) and Decapeptyl® (triptorelin)] amounted to over EUR 700 million in 2015, which was over half of Ipsen’s global…